Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.

Silvia La MonicaRoberta MinariDaniele CretellaLisa FlamminiClaudia FumarolaMara BonelliAndrea CavazzoniGraziana DigiacomoMaricla GalettiDenise MadedduAngela FalcoCostanza Annamaria LagrastaAnna SquadrilliElisabetta BarocelliAlessandro RomanelFederico QuainiPier Giorgio PetroniniMarcello TiseoRoberta Alfieri

Published in: Journal of experimental & clinical cancer research : CR (2019)

Our results identify a combination between osimertinib and pemetrexed or cisplatin potentially useful in the treatment of EGFR-mutated NSCLC patients, which might delay the appearance of osimertinib resistance with long-lasting effects.

Keyphrases

small cell lung cancer
advanced non small cell lung cancer
epidermal growth factor receptor
brain metastases
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
tyrosine kinase
prognostic factors
peritoneal dialysis
patient reported outcomes
replacement therapy